Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 321

Results For "PLI"

3733 News Found

Menarini Diagnositcs PCR kit identifies Omicron variant
Medical Device | January 18, 2022

Menarini Diagnositcs PCR kit identifies Omicron variant

It provides Covid-19 detection and Omicron surveillance in less than two hours


TPVI offers a ray of hope for children with Pulmonic Valve disease
Hospitals | January 18, 2022

TPVI offers a ray of hope for children with Pulmonic Valve disease

Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve


Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology
News | January 18, 2022

Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology

Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines


DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients
Biotech | January 18, 2022

DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients

The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)


We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure
interviews | January 17, 2022

We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure

The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment


Green Valley receives US FDA approval for Phase II clinical trial for Parkinson’s disease
Biotech | January 17, 2022

Green Valley receives US FDA approval for Phase II clinical trial for Parkinson’s disease

The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period


Strides receives USFDA approval for influenza medicine
Drug Approval | January 17, 2022

Strides receives USFDA approval for influenza medicine

The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval


AIIMS now uses ImmersiveTouch for surgeries
Digitisation | January 14, 2022

AIIMS now uses ImmersiveTouch for surgeries

Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training


Glenmark receives U.S. FDA approval for Ryaltris
Drug Approval | January 14, 2022

Glenmark receives U.S. FDA approval for Ryaltris

The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily


Evonik to build production plant for rhamnolipids in Slovakia
Biotech | January 14, 2022

Evonik to build production plant for rhamnolipids in Slovakia

The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years